Biologics therapies provide targeted injectable treatment for severe asthma, and are designed to block specific immune pathways that drive airway inflammation. However, its clinical responses remain highly heterogeneous. This variability suggests that severe asthma is developed not only by inflammation but by progressive lung structural remodeling over time.
To investigate this further, CHU Montpellier is using AI-driven quantitative CT analysis to characterize the lung structural changes such as airway dimensions, mucus plugs and trapped air throughout the course of biologic therapy.
LungQ AI-enabled quantitative image analysis contributes to the research by measuring bronchial widening (Bout/A and Bin/A) and wall thickening (Bwt/A and Bwa/Boa) using LungQ® BA, calculating mucus plug count and volumes using LungQ® MP, and assessing trapped air (low-attenuation region) using LungQ® VERA.
Detecting subtle yet clinically meaningful structural changes, the AI-powered analysis offer significantly higher precision and reproducibility, enabling exploration of how biologic therapies influence airway structure.
To learn more, read the blog featuring insights from Prof. Arnaud Bourdin, Head of Respiratory Medicine at the University of Montpellier.
